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Abstract 
Background: Patients of African ancestry with untreated HIV-1 infection and carrying the G1 or G2 kidney disease risk 
variants (Vs) at the APOL1 gene have a tenfold higher risk of developing HIV-associated nephropathy (HIVAN) com-
pared to those with the non-risk wild type (WT) G0 variant. However, the mechanistic contribution of the APOL1 allelic 
state to kidney injury in HIV-1 infection remains to be elucidated.
Results: Non-risk WT APOL1 is associated with lower intracellular levels of HIV-1 in conditionally immortalized human 
podocytes, while the over expression of G1 or G2 risk Vs significantly increases viral accumulation. The priming of 
podocytes with exogenous IL-1β facilitates HIV-1 entry, via the up-regulation of DC-SIGN. The over expression of 
APOL1 G1 and G2 risk Vs in combination with an increase in IL-1β levels causes a greater increase in viral concentra-
tion than either condition alone. In turn, HIV-1 and exogenous IL-1β together induce a de novo secretion of endog-
enous IL-1β and an increase of APOL1 gene expression.
Conclusions: Our findings indicate that the presence of risk Vs of APOL1 is permissive of HIV-1 persistence in human 
podocytes in synergy with IL-1β, a cytokine that characterizes the inflammatory milieu of acute and chronic phases 
of HIV-1 infection. The elucidation of these molecular mechanisms explains, at least in part, the higher frequency of 
HIVAN in populations carrying the risk polymorphic genetic variant of APOL1 gene.
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Background
HIV-1 associated nephropathy (HIVAN) is an important 
complication of HIV-1 infection and is characterized by 
collapsing focal segmental glomerulosclerosis (FSGS) and 
massive proteinuria [1, 2]. Different risk factors contrib-
ute to the pathogenesis of HIVAN. A longstanding high 
viral load is a major risk factor for the development of 
HIVAN [3–6]. Immune activation and chronic inflam-
mation are additional risk factors for the onset of HIVAN 
together with specific genetic mutations in the host 
[7–10]. Indeed, a direct association between kidney risk 
variants (Vs) of the Apolipoprotein L1 (APOL1) gene and 
the development of HIVAN had been reported [11–17]. 
These allelic Vs have been termed G1 (Ser342Gly and 
Ile384Met) and G2 (del.N388/Y389), in contrast to the 
non-risk wild type (WT) G0 allele. APOL1 is a minor 
component of plasma circulating High-Density Lipopro-
tein (HDL) endowed with the ability to kill Trypanosoma 
brucei responsible for African sleeping sickness [18–22]. 
The emerging resistance to the non-risk WT allele by 
Trypanosoma brucei gambiense and rhodesiense remark-
ably increased the frequency of the risk Vs of APOL1 in 
the residents of many regions of Sub-Saharan Africa as a 
consequence of pathogen selection pressure [23]. Intra-
cellular expression of APOL1 has been reported in sev-
eral cell types, including podocytes, and appears to be a 
lipid-binding protein relevant for cellular homeostasis 
Open Access
Retrovirology
*Correspondence:  joanna.mikulak@humanitasresearch.it;  
domenico.mavilio@unimi.it 
1 Unit of Clinical and Experimental Immunology, Humanitas Clinical 
and Research Center, Rozzano, Milan, Italy
Full list of author information is available at the end of the article
Page 2 of 12Mikulak et al. Retrovirology  (2016) 13:63 
through endosomal trafficking regulation, for lysoso-
mal function and autophagy ruling and for activation of 
innate immune response [24–28]. However, the molec-
ular mechanisms explaining the role of APOL1 in the 
pathogenesis of HIVAN remain elusive.
Podocytes are epithelial cells acting in conjunction with 
fenestrated endothelium and glomerular basement mem-
brane to ensure the integrity of the blood-urine barrier 
and glomerular filtration [29]. The challenge of study-
ing human primary podocytes is due to their terminally 
differentiated phenotype. Development of the HIVAN 
transgenic murine model and the use of conditionally 
immortalized human podocytes (CIHPs) have provided 
in  vivo and in  vitro models that have greatly advanced 
our understanding of HIVAN physiopathology [30–32]. 
In particular, it has been demonstrated that viral gene 
products directly induce pathologic changes in the phe-
notype and functions of podocytes such as deregulations 
of several host cellular pathways that involve cell cycle, 
oxidative stress, and apoptosis [33–39]. Data from kid-
ney biopsy of HIVAN patients also showed that podo-
cytes host and accumulate HIV-1 and serve as viral 
reservoirs in kidney [4, 40]. Finally, in vitro experiments 
demonstrated that human podocytes are able to capture 
HIV-1 and spread the virus by trans-infecting target cells 
[41–43].
Interleukin-1β (IL-1β) possesses a strong pro-inflam-
matory effect. Its production is tightly controlled by two 
steps: (1) induction of pro-IL-1β gene expression and (2) 
caspase-1-mediated cleavage of pro-IL-1β through the 
activation of the inflammasome complexes [44]. Several 
types of viruses, including hepatitis C virus and HIV-1 
have been found to induce the production of IL-1β 
through the induction of NLRP3 inflammasome [45, 
46]. Recently, increased secretion of bioactive IL-1β was 
observed to be relevant for inflammatory programmed 
cell death (pyroptosis) of CD4pos T cells with abortive 
HIV-1 infection [46]. Very little is known about the pos-
sible role of IL-1β in HIVAN pathogenesis.
Herein, we demonstrate that IL-1β in human podo-
cytes facilitates HIV-1 trafficking by greatly enhancing 
the uptake of the virus via the up-regulation of DC-SIGN 
receptor. High intracellular levels of HIV-1 in synergy 
with IL-1β increase the expression of APOL1 that can 
serve as a natural anti-viral restriction factor. Indeed, the 
non-risk WT APOL1 gene product inhibits HIV-1 accu-
mulation in podocyte, while the over expression of the 
APOL1 G1/G2 Vs increases the amount of HIV-1 in the 
same cells. These findings indicate that the allelic state of 
APOL1 is a key in determining the equilibrium between 
HIV-1 degradation and accumulation in human podo-
cytes, thus representing a critical pathogenic factor in the 
pathogenesis of HIVAN.
Results
APOL1 targets HIV‑1 trafficking in human podocytes
It has been previously reported that human podocytes 
constitutively express APOL1 [26, 27]. Our experiments 
of confocal microscopy showed that APOL1 protein is 
located in proximity of the cellular membrane of CIHPs 
and preferentially co-localize with early endocytosed 
vesicles expressing Rab5 protein and not with endosomes 
marker EEA1 required for endosomes maturation. On 
the other hand, we did not observe APOL1 co-localiza-
tion with either Rab7 or LAMP1 molecules which are 
expressed in late endosomes and lysosome compart-
ments respectively (Fig. 1a). These findings prompted us 
to study a possible role of APOL1 in regulating HIV-1 
entry and trafficking within human podocytes.
Since IFN-γ is a known inducer of APOL1 expression 
in podocytes [27, 28], CIHPs were pre-stimulated with 
IFN-γ. IFN-γ increases the APOL1 gene expression in 
CIHPs in a concentration-dependent manner (Fig.  1b). 
Previously it has been observed that in vitro experiments 
the capture of HIV-1 in human podocytes does not gen-
erate a productive virus replication [42, 43]. Therefore, 
to detect HIV-1 in podocytes we measured the spe-
cific HIV-1 strong stop DNA (RU5 HIV-1). This is pos-
sible because virions harbor strong-stop DNA since the 
endogenous reverse transcription of HIV-1 occurs prior 
to infection of target cells [47].
We then determined the viral entry in the podocytes 
by measuring the specific HIV-1 strong stop DNA con-
centration. Our data then demonstrated that the amount 
of HIV-1 significantly decreases in CIHPs treated with 
IFN-γ compared to their untreated counterparts (Fig. 1c). 
These results suggest that the IFN-γ-mediated up-regula-
tion of APOL1 interfere with the entry and/or early post-
entry steps regulating HIV-1 trafficking in podocytes. In 
this regard, we previously reported that HIV-1 internali-
zation in CIHPs is mediated by both lipids raft and DC-
SIGN receptor [41, 42]. However, IFN-γ treatment did 
not have any effect on DC-SIGN expression in podocytes 
(data not shown), thus ruling out a direct contribution 
of this inflammatory cytokine in limiting the viral entry 
in CIHPs through the modulation of this lectin-type 
receptor.
We then analyzed whether APOL1 plays a direct role 
in regulating HIV-1 accumulation in human podocytes. 
To this end, we transiently transfected CIHPs with the 
non-risk WT allele of APOL1. Similar to CIHPs stimu-
lated with IFN-γ, we found that increased expression of 
WT APOL1 significantly decrease the levels of HIV-1 
compared with CIHPs transfected with an empty control 
vector (Fig.  2a). We then proceeded to assess the effect 
of risk G1 and G2 APOL1 allelic Vs on HIV-1 accumula-
tion in CIHPs stably transfected with either WT or G1/
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G2 APOL1 Vs. In contrast with non-risk WT APOL1, 
the over expression of the G1 or the G2 APOL1 Vs sig-
nificantly increased HIV-1 levels in CIHPs (Fig.  2b), 
thus demonstrating that these risk Vs of APOL1facilitate 
HIV-1 accumulation and persistence in human podo-
cytes. The higher amounts of virus in CIHPs transfected 
with the G1 or the G2 APOL1 Vs also induced a signifi-
cant higher trans-infection of co-cultured CD4pos T cells 
that showed a significant increase of viral replication 
compared to that exerted by CIHPs transfected with WT 
APOL1 allele (Fig. 2c).
We also assessed in podocytes the transcriptional lev-
els of TFEB, the master transcription factor that regulates 
lysosome biosynthesis and whose activity is regulated by 
APOL1 expression [28, 48]. In addition, in human mac-
rophages APOL1-dependent expression of TFEB was 
associated with high HIV-1 Gag protein degradation [28, 
48]. Although, we did not observe differences in TFEB 
gene expression in WT APOL1 transfected podocytes, 
over expression of G1/G2 Vs of APOL1 significantly 
decrease the TFEB gene expression in CIHPs com-
pared to that of cells transfected with WT APOL1 allele 
(Fig. 2d). These findings suggest that the APOL1 risk Vs 
may promote HIV-1 accumulation in human podocytes 
through the disruption of endosomal/lysosomal pathway 
regulation.
IL‑1β facilitates HIV‑1 entry in human podocytes 
via DC‑SIGN and increases viral accumulation
The establishment of inflammation together with the 
pathologic production of several pro-inflammatory 
cytokines is a hallmark of HIV-1 infection. In particular, 
Fig. 1 Increased expression of WT APOL1 inversely correlates to HIV-1 persistence in CIHPs. a Summary graph of statistical dot plots (left panel) 
showing the co-localization off WT APOL1 with Rab5, Rab7, EEA1 and LAMP1 as an average measured by Pearson’s Coefficient on data analyzed 
with the Olympus FLUOVIEW FV1000 confocal microscope software (N = 3). Representative fluorescent microscopic images (right panel) showing 
the co-localization of WT APOL1 (red) with Rab5, Rab7, EEA1 and LAMP1 (green) marked vesicles and plasma membrane in CIHPs. Nucleuses are 
stained with DAPI in blue. b Statistical histogram graph showing the dose-dependent response of APOL1 gene expression after IFN-γ stimula-
tion (16 h). Results are expressed as relative fold change in IFN-γ treated CIHPs versus untreated controls (Ctrl) and normalized to GAPDH gene 
expression (N = 4). c Statistical histogram graph showing HIV-1 accumulation in CIHPs incubated for 16 h with IFN-γ (10 ng/mL) compared to their 
untreated counterparts (Ctrl). Results are expressed as relative fold change of HIV-1 DNA RU5 in IFN-γ treated cells versus Ctrl and normalized to 
GAPDH gene (N = 4). P values *<0.05, **<0.01; ***<0.001
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the increased systemic levels of IL-1β have been found 
in the sera of HIV-1 infected patients both in acute and 
chronic phases of the disease [49–52]. More recently, it 
has also been reported that abortive infection of HIV-1 
in CD4pos T cells induces an inflammatory programmed 
cell death (i.e. pyroptosis) caused by the release of pro-
inflammatory cytokines including IL-1β [46]. Further-
more, an increased expression of inflammasome markers 
such as IL-1β and caspases-1 was observed in the renal 
cortex of HIV-transgenic mice (Tg26) [53]. This experi-
mental evidence prompted us to analyze the direct effect 
of exogenous rhIL-1β on CIHPs at different time points. 
We found that the stimulation of CIHPs with 25 ng/mL 
of rhIL-1β induce a rapid and significant increase of IL-
1β gene expression that reached a plateau after 6  h of 
incubation (Fig.  3a). This phenomenon appeared to be 
also dose-dependent as the maximum response was 
reached at the concentration of 1.0  ng/mL of rhIL-1β 
(Fig.  3b). Moreover, the incubation of rhIL-1β-primed 
CIHPs with HIV-1 also induced a significantly higher 
IL-1β transcription levels compare to CIHPs stimulated 
with rhIL-1β alone (Fig. 3c). Nevertheless, the treatment 
of CIHPs with HIV-1 alone did not induce any increase 
of the IL-1β gene expression nor any release of detectable 
levels of IL-1β in cell supernatant (Fig. 3d). Only the stim-
ulation of podocytes with rhIL-1β followed by incubation 
Fig. 2 APOL1 polymorphism regulates HIV-1 persistence in CIHPs. a Statistical histogram graph showing HIV-1 accumulation in CIHPs transiently 
transfected with a APOL1-WT expressing vector compared to the control vector (Ctrl) following a time course incubation (3 and 6 h) with the virus. 
Results are expressed as relative fold change of HIV-1 DNA RU5 in APOL1-WT transfected cells compared to Ctrl and normalized to GAPDH gene 
(N = 4). b Time-course experiments showing the HIV-1 accumulation in CIHPs stable transfected with the control vector (Ctrl) or the specific APOL1-
WT or APOL1-G1/G2 expressing vectors. Results are expressed as relative fold change of HIV-1 DNA RU5 in HIV-1 incubated CIHPs versus non HIV-1 
treated cells and normalized to GAPDH gene (N = 4). c Rescue of infectious HIV-1 by CD4pos T lymphocytes co-cultured in time-course experiments 
(1, 3, 5 and 7 days) with HIV-1 pulsed CIHPs stable transfected with APOL1-WT or APOL1-G1 or APOL1-G2 compared with cells transfected with 
control vector (Ctrl). Since HIV-1 internalization in human podocytes is characterized by an abortive HIV-1 infection, cell lysates were collected and 
analyzed by qPCR for HIV-1 Gag gene not present in podocytes and indicative of a productive infection in CD4pos T cells. Results are expressed as 
fold increased of HIV-1 DNA Gag gene in PBMC co-cultured with HIV-1-pulsed CIHPs transfected with APOL1-WT or APOL1-G1 or APOL1-G2 or an 
empty vector (Ctrl) compared to their HIV-1 untreated counterparts and normalized to the amount of GAPDH gene (N = 4). d Statistical histogram 
graph showing TFEB gene expression in CIHPs transiently transfected with control vector (Ctrl) or APOL1-WT or APOL1-G1 or APOL1-G2 express-
ing vector. Results are expressed as fold change of transfected cells compared to Ctrl and normalized to the expression of GAPDH gene (N = 4). P 
values: *<0.05, **<0.01; ***<0.001
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with HIV-1 induced a detectable secretion of endogenous 
IL-1β (Fig.  3d). These data suggest that increased levels 
of circulating IL-1β in the glomerular milieu of HIV-1 
infected patients can induce a pathologic inflammatory 
loop that leads to the production and secretion of endog-
enous IL-1β by human podocytes.
We then assessed the effect of rhIL-1β in viral traffick-
ing within human podocytes by stimulating CIHPs with 
25 ng/mL of rhIL-1β for 16 h followed by incubation with 
HIV-1. Cells were harvested at different time-points and 
HIV-1 strong stop DNA was measured by qPCR. The 
priming of CIHPs with rhIL-1β significantly increased 
the amount of HIV-1 compared to podocytes incubated 
in the absence of rhIL-1β (Fig. 3e). The higher concentra-
tion of HIV-1 in rhIL-1β-primed CIHPs also induced a 
significantly higher trans-infection of co-cultured CD4pos 
Fig. 3 IL-1β increases HIV-1 accumulation in CIHPs. a Time and b dose response of IL-1β gene expression in unstimulated (Ctrl) and rhIL-1β treated 
CIHPs. Results are expressed as relative fold change in rhIL-1β treated cells versus Ctrl and normalized to GAPDH gene expression (N = 3). c Statisti-
cal histogram graph showing the IL-1β gene expression in CIHPs untreated (Ctrl), treated with rhIL-1β alone (25 ng/mL) for 16 h or incubated with 
HIV-1 either alone (6, 24 h) or with IL-1β (6, 24 h). Results are expressed as fold change of IL-1β gene expression in treated cells versus Ctrl and 
normalized to the GAPDH gene expression (N = 5). d Statistical histogram graph showing the amount of IL-1β protein secretion by CIHPs primed 
with rhIL-1β (25 ng/mL) and subsequently incubated with HIV-1 for 6 h compared to their counterparts incubated with rhIL-1β alone, HIV-1 alone or 
untreated cells (Ctrl) (N = 5). e Time course experiments showing HIV-1 accumulation in CIHPs either untreated (Ctrl) or pre-stimulated with rhIL-1β 
(25 ng/mL) for 16 h and followed by incubation with HIV-1 at different time points (3, 6, 24, 48, 72 h). Results are expressed as relative fold change 
of HIV-1 DNA RU5 in HIV-1 treated cells compared to their HIV-1 untreated counterparts for both experimental settings and normalized to GAPDH 
gene (N = 5). f Statistical histogram graph showing the rescue of infectious HIV-1 by CD4pos T lymphocytes co-cultured for 3 and 5 days with 
HIV-1-pulsed CIHPs either primed or none (Ctrl) with rhIL-1β. Since HIV-1 internalization in human podocytes is characterized by an abortive HIV-1 
infection, cell lysates were collected and analyzed by qPCR for HIV-1 Gag gene not present in podocytes and indicative of a productive infection 
in CD4pos T cells. Results are expressed as relative fold change of DNA HIV-1 Gag copies in rhIL-1β treated compared to Ctrl and normalized to DNA 
copies of GAPDH gene (N = 5). P values: *<0.05, **<0.01
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T lymphocytes that showed an increase of viral replica-
tion compared to that exerted by CIHPs not primed 
with rhIL-1β (Fig. 3f ). Given that HIV-1 entry in CIHPs 
depends on DC-SIGN expression [42] we than analyzed 
the transcripts levels of DC-SIGN in podocytes following 
stimulation with rhIL-1β. The incubation with rhIL-1β 
induced a rapid and significant increase of DC-SIGN 
gene expression in CIHPs (Fig. 4a). These results indicate 
that the inflammatory loop triggered by rhIL-1β is per-
missive of HIV-1 internalization in CIHPs via the up-reg-
ulation of DC-SIGN, which represent an already reported 
mechanism employed by HIV-1 to enter in these cells 
[42].
RhIL-1β increases expression of DC-SIGN also in 
CIHPs stably transfected with either WT or G1/G2 
APOL1 Vs (Fig. 4b), therefore, we used this experimen-
tal model to test the direct impact of rhIL-1β priming on 
HIV-1 entry and trans-infection to CD4pos T lympho-
cytes in the context of APOL1 polymorphism. RhIL-1β 
priming in both G1 and G2 APOL1 risk Vs was associ-
ated with the significantly increased accumulation of 
HIV-1. This phenomenon was correlated with the higher 
Fig. 4 APOL1 polymorphism affects IL-1β-dependent persistence of HIV-1 in CIHPs. a Time course experiments showing DC-SIGN gene expression 
in CIHPs after stimulation with rhIL-1β (25 ng/mL) compared to untreated cells (Ctrl) and normalized to GAPDH gene expression (N = 3). b Statistical 
histogram graph showing DC-SIGN gene expression after 18 h of rhIL-1β (25 ng/mL) treatment in CIHPs stably transfected with either empty vector 
(Ctrl) or WT or APOL1 risk Vs. Results are expressed as relative fold change in rhIL-1β treated cells versus non treated cells (Mock) and normalized 
to GAPDH gene expression (N = 3). c Statistical histogram graph showing HIV-1 accumulation after rhIL-1β stimulation in CIHPs stably transfected 
with the control vector (Ctrl) or the specific APOL1-WT or APOL1-G1/G2 expressing vectors. Results are expressed as relative fold change of HIV-1 
DNA RU5 in HIV-1 incubated CIHPs versus non HIV-1-pulsed cells (Mock) and normalized to GAPDH gene (N = 3). d Rescue of infectious HIV-1 by 
CD4pos T lymphocytes co-cultured in time-course experiments (0, 5 and 7 days) with HIV-1 pulsed CIHPs stable transfected with control vector 
(Ctrl), APOL1-WT or APOL1-G1/G2 Vs and pretreated or not (Mock) with rhIL-1β. Results are expressed as fold increased of HIV-1 DNA Gag gene in 
PBMC co-cultured with HIV-1 pulsed CIHPs compared to their HIV-1 untreated counterparts and normalized to the amount of GAPDH gene (N = 3). 
Horizontal lines represent Mock and rhIL-1β in the Ctrl sample depicting the fold change in HIV-1 replication. e APOL1 gene expression in CIHPs 
incubated with rhIL-1β (25 ng/mL) and subsequently treated with HIV-1 for 6 h compared to their counterparts incubated with rhIL-1β alone, HIV-1 
alone or untreated (Ctrl) Results are expressed as relative fold change normalized to GAPDH gene expression (N = 5). f Statistical histogram graph 
showing the APOL1 gene expression in CIHPs incubated with IL-1β (25 ng/mL) and subsequently treated with HIV-1 for 6 h either in pre absence 
(Ctrl) or in the presence of blocking anti-DC-SIGN mAb. Results are expressed as relative fold change in treated cells normalized to GAPDH gene 
expression (N = 3). P values *< 0.05, **< 0.01
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trans-infection of CD4pos T lymphocytes compared to the 
non treated cells with rhIL-1β (Fig. 4c). Podocytes trans-
fected with APOL1 WT and pre-treated with rhIL-1β 
also resulted with the significant upper trans-infection of 
CD4pos T lymphocytes after 5 days of co-culture (Fig. 4d). 
Nevertheless, over expression of APOL WT in rhIL-1β 
pre-stimulated cells showed lower virus concentration 
versus rhIL-1β-primed CIHPs transfected with empty 
vector. These results confirmed that only the presence of 
APOL1 WT, and not of APOL1 Vs, is associated with the 
control of HIV-1 entry and accumulation in podocytes.
In addition, we found that the incubation of CIHPs 
with rhIL-1β and HIV-1 together is required to raise the 
level of APOL1 gene expression, as neither rhIL-1β nor 
HIV-1 alone induced a significant increase of its tran-
script when compared to control experiments (Fig.  4e). 
To verify whether the up-regulation of APOL1 expres-
sion in rhIL-1β-primed CIHPs is dependent on HIV-1 
binding to DC-SIGN receptor, cells were pre-treated with 
a masking anti-DC-SIGN mAb before incubation with 
HIV-1. We found that the blocking of DC-SIGN induced 
a significant decrease of APOL1 gene expression, thus 
reversing the up-regulation of this apolipoprotein in 
response to simultaneous stimulation given by rhIL-1β 
and HIV-1 (Fig. 4f ).
Discussion
The pathogenic role of APOL1 is emerging in several kid-
ney diseases targeting podocytes and strong association 
between APOL1 high-risk Vs and progressive non-dia-
betic kidney disease [15, 26, 54], FSGS and HIVAN [11–
17] have been reported. The present study demonstrates 
that risk G1 and G2 variants of APOL1 enhances HIV-1 
accumulation and persistence in human podocytes, and 
also contributes to spread infection to neighbor CD4pos 
T cells. This process is amplified by IL-1β, whose priming 
of human podocytes increases viral entry and, together 
with HIV-1 itself, up-regulates the APOL1 gene expres-
sion (Fig. 5).
Previous in vitro studies reported that the over expres-
sion of APOL1 in podocytes induces lysosomal swelling 
and cell death with the G1 and G2 risk variants exert-
ing stronger effects at a lower threshold compared to the 
non-risk WT APOL1 [55]. The present study first sought 
to examine the impact of APOL1 polymorphism in regu-
lating HIV-1 trafficking in human podocytes. Indeed, 
these cells are able to capture HIV-1 that, instead of fully 
replicating to generate a productive infection, is rapidly 
degraded [42, 43]. We demonstrate here that the trans-
fection of non-risk WT APOL1 allele in CIHPs decreases 
the intracellular concentration of HIV-1, thus highlight-
ing that the WT variant of APOL1 serves as a natural 
anti-viral restriction factor in podocytes. Our additional 
experimental evidence showing that the expression of 
APOL1 is increased in rhIL-1β-primed podocytes fol-
lowing HIV-1 entry further supports this hypothesis. 
In this regard, it has been also shown that the anti-viral 
cytokine IFN-γ is able to greatly increase the expression 
of APOL1 [27] that, in turn, can target multiple steps of 
HIV-1 replication cycle in monocytes with the final result 
of inducing viral endocytosis and degradation within 
lysosome compartments [28]. Our data confirmed that 
also the stimulation of CIHPs with IFN-γ induce higher 
transcription levels of APOL1 that, as an intracellular 
protein, co-localize with Rab5 early endosomes. Of note, 
it has been already reported that Rab5 early endosomes 
regulate the homeostasis of endosomal pathway of podo-
cytes [56], and that binding of HIV-1 to DC-SIGN leads 
to an internalization of the virus in early Rab5 positive 
endosomes [57]. These findings suggest that the IFN-γ-
mediated up-regulation of APOL1, together with DC-
SIGN-mediated uptake of the virus, likely play a major 
role in endocytic trafficking and degradation of HIV-1 
also in human podocytes.
Another important contribution to antiviral responses 
of podocytes might occur as a consequence of the inflam-
matory processes that characterize both acute and 
chronic HIV-1 infection. In particular, both circulating 
and tissue resident immune cells (i.e. monocytes/mac-
rophages, T CD4pos lymphocytes, gut epithelial cells, 
etc.) have been reported to produce high amount of 
IL-1β that, in turn, boost local and systemic inflamma-
tion during the course of HIV-1 disease [46, 50, 58–60]. 
Indeed, high levels of IL-1β have been found in the sera 
of HIV-1 infected patients [61–63]. Although the harm-
ful effect of this potent cytokine in increasing viral repli-
cation and in directly damaging several immune and not 
immune cells both in blood and tissue have been exten-
sively reported [46, 59, 60, 64–66], little is known about 
the pathogenic role of IL-1β in HIV-1 targeted podo-
cytes. Recently, it has been shown in a murine HIVAN 
model (Tg26) that HIV-1 induces the activation of the 
inflammasome in podocytes [53]. We show here that 
the stimulation of podocytes with exogenous rhIL-1β 
induces a de novo IL-1β gene transcription. However, the 
secretion of bioactive endogenous IL-1β requires a sec-
ond signal delivered by HIV-1 following its uptake and 
internalization in podocytes. In this regard, we already 
reported the HIV-1 entry in human podocytes is mainly 
mediated by DC-SIGN [42], a lectin-type surface recep-
tor able to bind HIV-1 in a CD4-independent manner 
and promote trans-infection to CD4pos T cells [67]. Addi-
tionally, we also demonstrate here that in vitro stimula-
tion of CIHPs with rhIL-1β increases the expression of 
DC-SIGN, thus explaining both the higher accumulation 
of HIV-1 in rhIL-1β-primed podocytes and the increased 
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trans-infection of co-cultured CD4pos T cells. Hence, 
the priming with rhIL-1β facilitates viral entry into 
podocytes and triggers a harmful and vicious loop that 
increases viral spreading and induces a de novo secre-
tion of endogenous IL-1β by podocytes. In this regard, 
it has also been reported that under inflammatory stress 
podocytes can serve as non-hematopoietic professional 
antigen-presenting cells that up-regulate the expression 
of MHC class-II molecules [68–70]. The elucidation of 
these mechanisms in the context of the inflamed glomer-
ular milieu of HIV-1 infected patients containing high 
levels of IL-1β help us to better understand the patho-
logical changes observed in kidneys that ultimately cul-
minate in cell injuries and organ failure [36–39].
In the context of the HIV-1 driven inflammation in 
kidney, we demonstrate that the non-risk WT variant 
of APOL1 is endowed with natural antiviral activity that 
limits HIV-1 accumulation in podocytes. Indeed, our 
data showing that rhIL-1β priming in synergy with HIV-1 
increases the gene expression of this apolipoprotein in 
podocytes via the up-regulation of DC-SIGN explain, 
at least in part, the low incidence of HIVAN in the gen-
eral population carrying the WT APOL1. This is not the 
case for those populations carrying the risk G1 and G2 
polymorphic variants of APOL1 that, following HIV-1 
infection, experience a much higher frequency of HIVAN 
development [11–17]. The present study demonstrates 
that the over expression of these latter risk Vs of APOL1 
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Fig. 5 Mechanistic insights regulating HIV-1 entry and persistence in human podocytes. High levels of IL-1β both in tissues and in blood charac-
terize acute and chronic HIV-1 infection and can prime human podocytes in the context of the inflamed microenvironment of kidney glomerula. 
Indeed, exogenous IL-1β enhances HIV-1 entry via the up-regulation of DC SIGN and induces the production/secretion of endogenous IL-1β. In turn, 
the presence of both IL-1β and HIV-1 increase the expression of APOL1 within podocytes. In this context, the non-risk WT variant of APOL1 is key to 
control viral accumulation within podocytes and limit HIV-1 boarding. On the other side, the alternative presence of the high-risk G1 or G2 polymor-
phic variants of APOL1 increase the accumulation of HIV-1 in podocytes, thus worsening the vicious pathogenic inflammatory loop in podocytes. 
This can explain, at least in part, the higher frequency of HIVAN in populations carrying the high-risk genetic variants of APOL1 gene
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is associated with significantly higher HIV-1 accumula-
tion in podocytes, thus representing a relevant risk fac-
tor for the onset of HIVAN. Furthermore, the expression 
of APOL1 G1 and G2 risk Vs in combination with an 
increase in IL-1β levels causes a greater increase in viral 
concentration than either condition alone. Since, the 
risk Vs of APOL1 inhibit in podocytes the gene expres-
sion of TFEB, a master transcription factor that regulates 
lysosome biosynthesis [48], this strongly suggests that the 
increased boarding of HIV-1 in the podocytes carrying 
the G1 or G2 APOL1 polymorphism is due to a defec-
tive viral clearance. Furthermore, it has been previously 
reported that only APOL1 risk Vs could induce lyso-
somal leakage in podocytes effects at a lower threshold 
compared to the non-risk WT APOL1 [55]. The reversal 
from clearance to enhanced boarding of HIV-1 as a func-
tion of the non-risk WT versus risk G1 or G2 alleles state 
of APOL1, may explain why, of all podocytopathic kid-
ney diseases, HIVAN shows the most striking odds ratio, 
reading >89 in one recent study [71].
Conclusions
The present study demonstrates that APOL1 risk poly-
morphic Vs have a great impact in increasing uptake, 
accumulation and persistence of the HIV-1 in human 
podocytes. The inflammatory milieu that characterizes 
HIV-1 infection both at systemic and tissue levels can 
enhance this pathologic loop via the IL-1β priming. This 
explains, at least in part, the higher frequency of HIVAN 
in populations carrying the G1 and G2 genetic variants of 
APOL1 gene (Fig. 5).
Methods
Cells and virus
Conditionally immortalized human podocytes (CIHPs) 
were developed and cultured as described in Saleem 
et  al. [30]. CIHPs were transiently transfected with the 
empty vector or pcDNA3-APOL1-WT or -APOL1-G1/
G2 expressing plasmid by using as a transfection reagent 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. Mean-
while 48–72 h following transfection cells were used for 
qPCR analysis or treated with HIV-1BaL. Stable G0/G1/
G2 APOL1 CIHPs were generated by retroviral infection. 
Briefly, the open reading frame APOL1 (G0, G1, G2) was 
cloned into the retroviral vector pBABE carrying resist-
ance to puromycin. To generate retroviral particles, the 
viral packaging cell line HEK-GP were co-transfected 
with the pBABE construct of interest and the VSV gene. 
CIHPs were infected twice within 24  h with the viral-
containing supernatant of HEK-GP cells. Selection with 
puromycin (1  μg/mL) was continued for a week, and 
comparable expression of respective sequence of the cor-
responding APOL1 was verified.
Human PBMCs were obtain from Buffy coats of 
healthy volunteers who signed consent forms in accord-
ance with the Declaration of Helsinki and with clinical 
protocols approved by the Institutional Review Board of 
Desio Hospital, Milan, Italy. PBMCs were isolated over 
Ficoll Paque™ Premium density gradients (GE Health-
care Bio-Sciences AB, Little Chalfont, Buckinghamshire, 
UK) and cultured in RPMI 1640 medium, supplemented 
with 10  % FBS, 2  mM  l-glutamine, 100  U/mL penicil-
lin/streptomycin and activated with 5  μg/mL of Lectin 
from Phaseolus vulgaris (PHA-L) (Sigma-Aldrich, Saint 
Louis, MO, USA) for 3  days PHA-L and subsequently 
with 200 IU/mL of human recombinant IL-2 (Peprotech, 
Rocky Hill, NJ, USA). In co-cultivation studies activated 
lymphocytes were added to podocytes at a ratio of 5:1 
in a RPMI complete medium supplemented with 200   
U/mL of IL-2. HIV-1BAL strain was expanded in activated 
PBMCs collected at the peak of virus replication. HIV-1 
p24 Ag concentrations in the culture supernatants were 
determined by ELISA (Aalto, Ratfharnham Village, Ire-
land) as described in [42].
Reagents
Human recombinant (h) IL-1β and interferon-γ were 
purchased from PeproTech. Human IL-1β secreted pro-
tein was measured in cell-free harvested supernatants by 
ELISA (DuoSet DY201, R&D System, Minneapolis, MN, 
USA). In blocking experiments CIHPs were pre-treated 
with rIL-1β, washed out and then incubated with con-
trol Isotype (Ctrl) or mouse anti-DC-SIGN monoclonal 
Ab (mAb) at the dose of 5 mg/mL (Abcam) before HIV-1 
treatment.
QPCR
For cellular gene expression total RNA was extracted 
using RNeasy mini columns (Qiagen, Valencia, CA, 
USA), following manufacturer’s instructions. One μg 
of total RNA was used to generate cDNA templates 
for RT-PCR, using random primers, RNase inhibitor 
and High-Capacity cDNA Reverse Transcription Kit 
from Applied Biosystem (Foster City, CA, USA). IL-1β, 
TFEB, DC-SIGN, WT-1, podocin, nephrin, synaptopo-
din and housekeeping S18 and GAPDH genes expres-
sion were analyzed by the TaqMan® mRNA specific 
assays. Followed primers were used for the SYBR Green 
PCR Master Mix analysis (Applied Biosystem): APOL1 
Fw-5′-ATCTCAGCTGAAAGCGGTGAAC-3′ and Rev- 
5′-TGACTTTGCCCCCTCATGTAAG-3′; 18S Fw-5′-AC 
TTTCGATGGTAGTCGCCGT-3′ and Rev-5′-CCTTGG 
ATGTGGTAGCCGTTT-3′.
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HIV‑1 detection
Viral stock before incubation with podocytes were 
treated (1  h at room temperature) with 200  U/mL of 
RNase-free DNase (Roche, Basel, Switzerland). Before 
preparation of cell lysates, control and HIV-1-pulsed 
cells were washed three times with PBS, then treated 
with 0.05  % trypsin at 37  °C for 10  min to eliminate 
non internalized virus, and subsequently washed 
five times with PBS. Cell lysates were prepared as 
described in Malnati et  al. [72] and subjected to qPCR 
TaqMan analysis by using HIV-1 specific primers: 
Gag Fw-5′-ACATCAAGCAGCCATGCAAAT-3′, Rev-
5′-ATCTGGCCTGGTGCAATAGG-3′ and probe 5′-CA 
TCAATGAGGAAGCTGCAGAATGGGATAGA-3′, 
LTR RU5 Fw-5′-GGCTAACTAGGGAACCCACTG-3′, 
Rev-5′-CTGCTAGAGATTTTCCACACTGAC-3′ and 
probe 5′-TGTGTGCCCGTCTGTTGTGTG-3′ [42, 73]. 
Amplification of GAPDH gene as a reference was used 
to control the amount of DNA in each sample (Applied 
Biosystem).
Fluorescence confocal microscopy
CIHPs were growth on the coverslip’s coated with human 
collagen IV then were fixed with 4 % paraformaldehyde, 
followed by permeabilization and blocking with 0.3  % 
Triton X-100 and 10 % goat serum. Immunoblotting with 
the followed primary antibodies were performed: Mouse 
monoclonal anti-APOL1, anti-DC-SIGN and rabbit poly-
clonal anti-podocin purchased from Abcam; Rabbit poly-
clonal anti-Rab5, -Rab7, -EEA, -Lamp1 purchased from 
Life Technolgies.
Statistical analysis
The significance of the data was assessed using Student’s t 
test statistical analysis. Data shown are mean ± S.D. The 
number of experiments is specified in the Figure legends. 
In the figures statistical significance (P) is indicated by 
asterisks (*). *P < 0.05; **P < 0.01; ***P < 0.001.
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